The role of statin therapy in patients with chronic kidney disease

Clinical Geriatrics

Volumn 14, Issue 6, 2006, Pages 29-34

  Decker, Brian S ^a   Molitoris, Bruce A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CYTOKINE; DOBUTAMINE; EZETIMIBE; FLUINDOSTATIN; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG FATALITY; DYSLIPOPROTEINEMIA; ENZYME INHIBITION; HEART INFARCTION; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PATIENT CARE; PROTEIN SYNTHESIS INHIBITION; RENAL PROTECTION; RISK BENEFIT ANALYSIS;

EID: 33745601643     PISSN: 10951598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes af Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004.
2. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-1129.
3. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis 2002;39(suppl 1):S1-S266.
4. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 suppl 3):S112-S119.
5. Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003;S24-S31.
6. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001;135: 447-459.
7. Bloomfield Rubins H. The trouble with triglycerides. Arch Intern Med 2000;160:1903-1904.
8. Gianturco SH, Bradley WA. Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia. Semin Thromb Hemost 1988;14(2):165-169.
9. Quaschning T, Krane V, Metzger T, Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 2001;38(4 suppl 1):S14-S19.
10. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-1036. [Erratum in: Circulation 1998;97(19):1995.]
11. Krauss RM. Triglycerides and atherogenic lipoproteins: Rationale for lipid management. Am J Med 1998; 105(1A):58S-60S.
12. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21(6):573-592.
13. Appel GB, Appel AS. Dyslipidemia in chronic kidney disease and end-stage renal disease: A review. Dial Transplant 2004; 33 (11):714-719.
14. Prinsen BH, de Sain-van der Velden MG, de Koning EJ, et al. Hypertriglyceridemia in patients with chronic renal failure: Possible mechanisms. Kidney Int Suppl 2003;(84):S121-S124.
15. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991;31:S29-S34.
16. Keane WF, Mulcahy WS, Kasiske BL, et al. Hyperlipidemia and progressive renal disease. Kidney Int Suppl 1991;31:S41-S48.
17. Moorhead JF. Lipids and progressive kidney disease. Kidney Int Suppl 1991;31:S35-S40.
18. Tonelli M, Moyé L, Sacks FM, et al; Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003;138:98-104.
19. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005;16:3748-3754.
20. Fathi R, Isbel N, Short L, et al. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 2004;43(1): 45-52.
21. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC, for the Cholesterol and Recurrent Events (CARE) Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605-1613.
22. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-734.
23. Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004;102: 52-60.
24. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl 1999;71:S2-S5.
25. Sidaway JE, Davidson RG, McTaggart F, et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004;15:2258-2265.
26. Afzal B, Haydar AA, Vinen K, Goldsmith DJA. From Finland to fatland: Beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol 2004;15:2161-2168.
27. van Dijk MA, Kamper AM, van Veen S, et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16:2152-2157.
28. National Kidney Foundation. K/DOQI Clinical Practice Guidelines For Managing Dyslipidemias in Chronic Kidney Disease. Available at: www.kidney.org/professionals/kdoqi/guidelines_lipids/index.htm. Accessed March 23, 2006.
29. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239. [Erratum in: Circulation 2004;110(6):763.]
30. Chong PH. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Ann Pharmacother 2002;36(12): 1907-1917.
31. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: Implications for therapeutic selection. Am J Med 2001;111:390-400.
32. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;84:S207-S210.